Guillain-Barré Syndrome Market
Guillain-Barré Syndrome Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Guillain-Barré Syndrome Market Size and Growth
Guillain-Barré Syndrome (GBS) market research indicates a growing awareness of diagnostic and therapeutic advancements, leading to a robust market landscape. The global GBS market is projected to reach approximately $2.5 billion by 2028, driven by increasing incidence rates, enhanced treatment options, and rising healthcare investments in neurology. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Grifols
◍ CSL Behring
◍ Octapharma
◍ Nihon Pharmaceutical
◍ Akari Therapeutics
◍ China Biologic Products Holdings
◍ Biotest
◍ Kedrion
The Guillain-Barré Syndrome market features companies like Grifols, CSL Behring, and Octapharma, which provide immunoglobulin therapies. Akari Therapeutics and others focus on innovative treatments. These firms drive market growth through R&D, expanding product offerings, and enhancing patient access, contributing to an increasing revenue trend across the sector.
- Grifols: ~€5.3 billion (2022)
- CSL Behring: ~$9.6 billion (2022)
- Octapharma: €2 billion (2022)
Request Sample Report
Market Segmentation
By Application
◍ Hospital Pharmacies
◍ Retail Pharmacies
◍ Others
By Product
◍ Intravenous Immunoglobulin
◍ Plasma Exchange ◍ Others
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
